Establishing a reasonable price for an orphan drug
نویسندگان
چکیده
منابع مشابه
Methadone: An Orphan Drug?
73 Dear Editor: A pharmaceutical product is called “orphan drug” when, although promising or clearly valid from a scientific and therapeutic point of view, it is not profit-bearing and, therefore, not interesting for the pharmaceutical industry. The consequences are the lack of extensive research on its effects, and mainly, the lack of appropriate information to physicians, nurses, and administ...
متن کاملOrphan Drug Pricing: An Original Exponential Model Relating Price to the Number of Patients
In managing drug prices at the national level, orphan drugs represent a special case because the price of these agents is higher than that determined according to value-based principles. A common practice is to set the orphan drug price in an inverse relationship with the number of patients, so that the price increases as the number of patients decreases. Determination of prices in this context...
متن کاملDrug repositioning for orphan diseases
The need and opportunity to discover therapeutics for rare or orphan diseases are enormous. Due to limited prevalence and/or commercial potential, of the approximately 6000 orphan diseases (defined by the FDA Orphan Drug Act as <200 000 US prevalence), only a small fraction (5%) is of interest to the biopharmaceutical industry. The fact that drug development is complicated, time-consuming and e...
متن کاملOptimizing an Orphan Drug Framework for Canada Canada’s Orphan Drug Framework: Lessons from the United States, Europe and Japan
Canada is in the process of developing an orphan drug regulatory framework (the “Canadian Framework”) 1 in which an orphan drug is defined as one targeting a disease that affects fewer than 5 in 10,000 Canadians. The federal government announced the development of the Canadian Framework in 2012. Health Canada has held workshops and announced pilot projects related to the Canadian Framework, but...
متن کاملFinancing drug discovery for orphan diseases.
Recently proposed 'megafund' financing methods for funding translational medicine and drug development require billions of dollars in capital per megafund to de-risk the drug discovery process enough to issue long-term bonds. Here, we demonstrate that the same financing methods can be applied to orphan drug development but, because of the unique nature of orphan diseases and therapeutics (lower...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cost Effectiveness and Resource Allocation
سال: 2020
ISSN: 1478-7547
DOI: 10.1186/s12962-020-00223-x